Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 82

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 82
---
.

Net
loss and net loss attributable to common stockholders

For the three months ended
June 30, 2025 and 2024, net loss amounted to $5,417,000 and $2,449,000, respectively, which represents an increase in net loss of $2,968,000,
or 121.2%. During the three months ended June 30, 2025, in connection with our Series A, Series B and Series C preferred stock conversions,
we recorded deemed dividends of $24,700,000. Accordingly, for the three months ended June 30, 2025 and 2024, net loss attributable to
common stockholders amounted to $30,117,000, or $(61.71) per common share, and $2,449,000, or $(302.32) per common share, respectively.

Results
of Operations for the Six Months Ended June 30, 2025 and 2024

The
results of operations for the six months ended June 30, 2024 are pro forma as the period presented in the following table and
discussion includes the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from
February 14, 2024 through June 30, 2024. This pro forma period from January 1, 2024 to June 30, 2024 does not include the Merger transactions
that occurred on-the-line.

    For the Six Months Ended  June 30,  

    2024  

    2025 (Successor)  
    (Pro forma) (Predecessor and Successor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $5,661,790  
    $4,382,551  
    $1,279,239  
     29.2%
  
    General and administrative 
     4,012,532  
     5,317,756  
     (1,305,224) 
     (24.5)%
  
    Total operating expenses 
     9,674,322  
     9,700,307  
     (25,985) 
     (0.3)%
  
    Loss from operations 
     (9,674,322) 
     (